Pareto publishes research report increasing price target to SEK 99
Hørsholm, Denmark, March 1, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has updated their research reports on ExpreS2ion in March, following the publication of year-end 2021 results and the release of additional positive Phase II COVID-19 results for the ABNCoV2 vaccine. Pareto upheld its ‘buy’ rating and increased its price target from SEK 88 to SEK 99 per share, based on an increased likelihood of approval.The research report is available on the Analyst Reports